Incyte Corporation is making progress toward providing vitiligo patients with therapeutic options, as it presented Phase IIb data on 11 October at the European Academy of Dermatology and Venereology Congress showing that oral selective JAK1 inhibitor povorcitinib at multiple doses can improve facial or full-body depigmentation in patients with nonsegmental vitiligo.
The company already offers Opzelura (ruxolitinib), a topical formulation of the active ingredient in its JAK1/2 inhibitor Jakafi, as a therapy for vitiligo and atopic dermatitis. (Also see "Incyte Bolsters Dermatology Ambitions With Vitiligo Approval For Topical Ruxolitinib" - Scrip, 19 July, 2022
The 52-week supplemental data reported 11 October follows top-line 24-week data for povorcitinib in nonsegmental vitiligo that were released in March. In that dataset, patients in three separate dosing groups met the primary endpoint with statistically significant improvements in total Vitiligo Area Scoring Index (T-VASI) at week 24 compared to placebo. The 15mg cohort saw 19.1% improvement, the 45mg group had 17.8% improvement and the 75mg group had 15.7% improvement compared to placebo (p<0.01)